New York, NY 15 June 21: The global gout therapeutics market size is expected to reach USD 6,304.8 million by 2026 according to a new study by Polaris Market Research. The report “Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition (Acute, Chronic); By Regions, Segments & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The incidence and prevalence of gout has increased over two-fold in past 20 years. This growth combined with increasing occurrence of comorbid conditions and cardiovascular risk factors represents a significant public health challenge. Globally, the developed countries tend to have a higher burden of gout compared to the developing countries, and also have increasing prevalence of this disease. There are various factors including genetic history, and ethnicity that could lead to occurrence of gout. Also, socioeconomic and dietary factors, as well as comorbidities and medications that can influence uric acid levels and facilitate MSU crystal formation, are also important in determining the risk of developing clinically evident gout.
Request For Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/gout-therapeutics-market/request-for-sample
Furthermore, growing prevalence of this condition across the globe, increasing research and development activities, growing number of product approvals, and increasing public and private investments are some other factors driving the growth of the market during the forecast period. Recently, in New Zealand, the HRC funded Professor Lisa Stamp at the University of Otago to lead the first-ever randomized controlled trial demonstrating an improved dosing strategy using allopurinol to help more patients to manage their gout symptoms. Also, in 2019 researchers at Washington State University Health Sciences Spokane and elsewhere identified a new therapeutic target for the treatment of gout. Such growing research studies are fueling the growth of the market during the forecast period.
However, factors such as patent expiry of blockbuster products, increasing competition in the generic sector and high cost of the newly launched drugs are likely to hinder the growth of this market during the forecast period. The cost associated with gout therapies is poised to increase dramatically due to federal policy decisions and pipeline developments. Also, patent expiry of major blockbuster agents and expected launch of generic version are likely to restrain the growth of the market during the forecast period. Entry of generic after its patent expiry would decline the revenue in future. Hence, high cost of the products and patent expiry of the medicines is a key factor to restrain the growth of the market.
Furthermore, Europe also has a significant share in the global industry. Various international companies have been launching new products in the European market. For instance, in August 2018, Grünenthal received European approval for Duzallo (lesinurad/allopurinol) and extended its gout portfolio. However, Asia-Pacific is projected to witness a fastest growth during the forecast period. This highest growth is mainly anticipated due to the presence of several high economically growing countries such as India, China, South Korea, and other South Asian countries. Increasing number of people linked with smoking and alcohol consumption, growing population, increasing need for effective therapies, and growing expansion of local and international players in this regional segment are also fueling the growth of gout therapeutics market in this region.
To get Incredible Discounts on this Premium Report, Click At : https://www.polarismarketresearch.com/industry-analysis/gout-therapeutics-market/request-for-discount-pricing
The key players in the industry include AstraZeneca, Horizon Pharma Plc, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Teijin Pharma Limited, Regeneron Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and Grunenthal Group among others.
About Polaris Market Research
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for our clientele spread across different enterprises.
Contact Us:
Polaris Market Research
Phone: 1–646–568–9980
Email: [email protected]
New York, NY 16 Feb 21: The global gout therapeutics market size is expected to reach USD 6,304.8 million by 2026 according to a new study by Polaris Market Research.
The report “Gout Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Non-steroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Colchicine, Urate Lowering Agents) Disease Condition (Acute, Chronic); By Regions, Segments & Forecast, 2020 – 2026” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The incidence and prevalence of gout has increased over two-fold in past 20 years.
Globally, the developed countries tend to have a higher burden of gout compared to the developing countries, and also have increasing prevalence of this disease.
There are various factors including genetic history, and ethnicity that could lead to occurrence of gout.
Recently, in New Zealand, the HRC funded Professor Lisa Stamp at the University of Otago to lead the first-ever randomized controlled trial demonstrating an improved dosing strategy using allopurinol to help more patients to manage their gout symptoms.
gout therapeutics market Research Report: By Type (Tophaceous Gout and Pseudogout), By Treatment (Medication, Self-Care), By Diagnosis (Ct Scan, Ultrasound, Urine Test, Blood Test), And By End-User (Hospitals, Specialty Centers, Homecare) – Global Forecast Till 2023The gout therapeutics market analysis of the major companies in the report, sector of the report includes the market depictions, requirements, and product portrayals, manufacture, competence, contact figures, cost, and revenue.The report also appraises the supervisory scenarios which affect various decisions in the market.
With all the data congregated and scrutinized using SWOT analysis, there is a vibrant picture of the competitive scenario of the Global gout therapeutics market.
Openings for the future market growth were uncovered and preoccupied competitive threats also textured.The gout therapeutics market sample report will provide valuable insight with an emphasis on the global market including some of the major players such As, Takeda Pharmaceutical Company Ltd., Savient Pharmaceuticals, AstraZeneca plc, Merck& Co. Inc., Inc.Ardelyx, Inc., Astellas Pharma Inc., and Novartis AG.Reasons to Purchase this ReportQualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factorsProvision of market value (USD Billion) data for each segment and sub-segmentIndicates the region and segment that is expected to witness the fastest growth as well as to dominate the marketAnalysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each regionThe competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiledThe research analysts provide an elaborate description of the value chain and its distributor analysis.
This gout therapeutics market study provides comprehensive data which enhances the understanding, scope and application of this report.Access Complete Detailed TOC Research Report at https://www.marketresearchfuture.com/reports/gout-market-5909gout therapeutics market Research Coverage:Changing market dynamics of the industryTo get a comprehensive overview of the gout therapeutics market.Historical, current and projected market size in terms of volume and valueIn-depth market segmentationCompetitive landscapeAbout Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.Contact:Market Research Future+1 646 845 9312Email: [email protected]
The global gout therapeutics market size is expected to reach USD 6,304.8 million by 2026 according to a new study by Polaris Market Research.
The incidence and prevalence of gout has increased over two-fold in past 20 years.
Globally, the developed countries tend to have a higher burden of gout compared to the developing countries, and also have increasing prevalence of this disease.
Download Sample Copy @ https://www.polarismarketresearch.com/industry-analysis/gout-therapeutics-market/request-for-sample The key players in the industry include AstraZeneca, Horizon Pharma Plc, Takeda Pharmaceutical Company Limited, GlaxoSmithKline plc, Novartis AG, Merck & Co. Inc., Teijin Pharma Limited, Regeneron Pharmaceuticals, Inc, Ironwood Pharmaceuticals, Inc., JW Pharmaceutical, Selecta Biosciences, Inc., and Grunenthal Group among others.
According to the data published by the United Nations in 2012, global geriatric population was nearly 809.4 million in 2011 and is anticipated to grow more than double and reach over 2,000 million by 2050.
Recently, in New Zealand, the HRC funded Professor Lisa Stamp at the University of Otago to lead the first-ever randomized controlled trial demonstrating an improved dosing strategy using allopurinol to help more patients to manage their gout symptoms.
